Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Comparison
 
Forums
Visit our forums
 
Jobs
Visit our job site
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire New!
 
Contact us
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..7 of 7 - per page
Order by
Two new compounds having HDAC (histone deacetylase) inhibition capability have shown the effect of inducing re-differentiation of human brain and breast cancer cells both in vitro and in vivo. More
A number of specific PPLs, a group of prenylflavanone compounds, some novel, were isolated, identified and tested at as low as 0.04 μg/mL to be able to increase survival of neural stem cells, to promote neuronal growth with lengthening of neurite More
A novel non-invasive method for using carbon-13 magnetization transfer effects to determine and evaluate in vivo aspartate transaminase (AST) activity and levels in an organ, as a biomarker of disease and certain neurological disorders. More
The present invention provides assays for the detection of human RFX4_v3 polymorphisms or deficiencies that may lead to the determination of an individual's risk of developing hydrocephalus. More
These radioactive compounds have the very unique and unprecedented ability to bind very specifically and irreversibly to butyrylcholinesterase (BChE). More
2-arachidonylglycerol (2-AG) is used to inhibit tumor necrosis factor alpha (TNF alpha) and as a neuroprotector of the brain in closed head injury. 2-AG can be used also to reduce edema and neurological deficits caused by closed head injury. More
Incensole Acetate (IA), isolated from the resin of Boswellia carterii, provides an effective treatment for many conditions including acute inflammation and inflammatory-associated conditions (arthritis, asthma, inflammatory bowel disease, and... More
Displaying 1..7 of 7 - per page
Order by

Your selection

Therapeutic target
Central Nervous System del
Neurological del
Brain injury del

Browse By

Partnering consultation free of charge
Cell & Gene Therapy Forum 2009
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2008 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us